Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19
Resumen: The coronavirus disease 2019 (COVID-19) pandemic caused by the new coronavirus (SARS-CoV-2) is currently responsible for more than 3 million deaths in 219 countries across the world and with more than 140 million cases. The absence of FDA-approved drugs against SARS-CoV-2 has highlighted an urgent need to design new drugs. We developed an integrated model of the human cell and SARS-CoV-2 to provide insight into the virus'' pathogenic mechanism and support current therapeutic strategies. We show the biochemical reactions required for the growth and general maintenance of the human cell, first, in its healthy state. We then demonstrate how the entry of SARS-CoV-2 into the human cell causes biochemical and structural changes, leading to a change of cell functions or cell death. A new computational method that predicts 20 unique reactions as drug targets from our models and provides a platform for future studies on viral entry inhibition, immune regulation, and drug optimisation strategies. The model is available in BioModels (https://www.ebi.ac.uk/biomodels/MODEL2007210001) and the software tool, findCPcli, that implements the computational method is available at https://github.com/findCP/findCPcli. © 2021 Bannerman et al.
Idioma: Inglés
DOI: 10.26508/LSA.202000954
Año: 2021
Publicado en: Life Science Alliance 4, 10 (2021), e202000954 [13p]
ISSN: 2575-1077

Factor impacto JCR: 5.781 (2021)
Categ. JCR: BIOLOGY rank: 17 / 94 = 0.181 (2021) - Q1 - T1
Factor impacto CITESCORE: 6.5 - Agricultural and Biological Sciences (Q1) - Environmental Science (Q1) - Biochemistry, Genetics and Molecular Biology (Q2)

Factor impacto SCIMAGO: 2.318 - Biochemistry, Genetics and Molecular Biology (miscellaneous) (Q1) - Plant Science (Q1) - Ecology (Q1)

Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Lenguajes y Sistemas Inf. (Dpto. Informát.Ingenie.Sistms.)

Creative Commons Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.


Exportado de SIDERAL (2023-05-18-15:40:16)


Visitas y descargas

Este artículo se encuentra en las siguientes colecciones:
Artículos



 Registro creado el 2022-10-27, última modificación el 2023-05-19


Versión publicada:
 PDF
Valore este documento:

Rate this document:
1
2
3
 
(Sin ninguna reseña)